For 20 years, monoclonal antibodies (mAbs) have been a standard component of cancer
therapy, but there is still much room for improvement. Efforts continue to build better cancer …

Since the first description in 1989 of CD4‐Fc‐fusion antagonists that inhibit human immune
deficiency virus entry into T cells, Fc‐fusion proteins have been intensely investigated for …

Immunoglobulin A (IgA) has a critical role in immune defense particularly at the mucosal
surfaces, and is equipped to do so by the unique structural attributes of its heavy chain and …

Over the last decades, cancer immunotherapies such as checkpoint blockade and adoptive
T cell transfer have been a game changer in many aspects and have improved the treatment …

We live in a hostile environment but are protected by the innate and adaptive immune
system. A major component of the latter is mediated by antibody molecules that bind to …

Immunoglobulin A (IgA) is commonly recognized as the most prevalent antibody (Ab) at
mucosal sites with an important role in defense by shielding mucosal surfaces from invasion …

The use of monoclonal antibodies (mAbs) has become a mainstream strategy for the
treatment of cancer. After binding to the target antigen, they mediate a plethora of effector …

Currently all approved anti‐cancer therapeutic monoclonal antibodies (mAbs) are of the IgG
isotype, which rely on Fcgamma receptors (FcγRs) to recruit cellular effector functions. In …

Antibody-based immunotherapy is a promising strategy in cancer treatment. Antibodies can
directly inhibit tumor growth, induce complement-dependent cytotoxicity and induce Fc …

Monoclonal antibodies (mAbs) have become an important addition to chemo-and/or
radiotherapy for the treatment of cancer. They have multiple effector functions that can lead …